Monday, December 23, 2024
Facebook Linkedin Twitter
HomeTagsAntibody-drug conjugate

antibody-drug conjugate

Biotechnology

RemeGen’s RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

PR Newswire -
RemeGen Co., Ltd. , a commercial-stage biotechnology company, announced on December 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted...
Biotechnology

RemeGen’s Telitacicept and Disitamab Vedotin Enter China’s National Reimbursement Drug List for SLE and Gastric Cancer Treatment

PR Newswire -
RemeGen Co., Ltd., a commercial-ready biotechnology company, announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us